Predictive Factors for the Efficacy of Radioactive Iodine Treatment of Graves' Disease

被引:0
作者
Feng, Wenwen [1 ,2 ]
Shi, He [3 ]
Yang, Yanli [1 ]
Liu, Jing [4 ]
Chen, Shiying [1 ]
Ren, Minghui [1 ]
Li, Yajie [1 ]
Liu, Wei [3 ]
Cui, Dai [1 ]
机构
[1] Nanjing Med Univ, Affiliated Hosp 1, Dept Endocrinol, Nanjing, Jiangsu, Peoples R China
[2] Xuzhou Med Univ, Affiliated Huaian Hosp, Dept Geriatr, Huaian, Jiangsu, Peoples R China
[3] Nanjing Med Univ, Affiliated Hosp 1, Dept Nucl Med, Nanjing, Jiangsu, Peoples R China
[4] Nanjing Med Univ, Affiliated Hosp 1, Dept Geriatr Endocrinol, Nanjing, Jiangsu, Peoples R China
关键词
RADIOIODINE THERAPY; I-131; THERAPY; PROGNOSTIC-FACTORS; CLINICAL-OUTCOMES; HYPERTHYROIDISM; MANAGEMENT; TURNOVER; FAILURE;
D O I
10.1155/2024/7535093
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The utilization of radioactive iodine-131I (RAI) has long been established as a cost-effective and conventional treatment for managing Graves' disease (GD). However, the accurate prediction of the clinical response to RAI treatment remains difficult. The successful resolution of GD through RAI therapy is typically characterized by the induction of hypothyroidism or euthyroidism. Thus, the principal aim of this study was to identify plausible predictors of RAI efficacy in the treatment of GD.Methods: The clinical data of 613 GD patients, who underwent RAI treatment for the first time, were retrospectively analyzed, including age, gender, duration of hyperthyroidism, presence or absence of ocular signs, thyroid volume, thyroid weight, thyroid function (FT3, FT4, and TSH), radioactive iodine uptake (RAIU) at 2 h/6 h/24 h (2-h/6-h/24-h RAIU) prior to RAI treatment, the highest RAIU (RAIUmax), and administered activity of 131I and 131I activity per gram of thyroid tissue. Success of RAI treatment was defined as achieving hypothyroidism or euthyroidism for more than 1 year after the initial treatment. Univariate and multivariate logistics regression analyses were conducted to identify factors that influence the efficacy of RAI treatment for GD. And at last, based on the results of the multivariate logistic regression analysis, a nomogram model was established.Results: In this study, the success rate of RAI treatment for GD was 91.2% (559/613). Univariate analysis demonstrated that several factors, including age (p=0.005), thyroid volume (p=0.001), thyroid-stimulating hormone (TSH, p=0.042), ratio of RAIU at 6 h to 24 h (6-h/24-h RAIU, p=0.048), total 131I activity (p=0.026), and 131I activity per gram of thyroid tissue (p=0.001), were significantly associated with treatment outcome. Multivariate logistic regression analysis indicated thyroid volume and 131I activity per gram of thyroid tissue as significant independent predictors of radioactive iodine therapy (RIT) efficacy. The area under the ROC curve of the established nomogram model was 0.769 (95% confidence interval [CI]: 0.692-0.846), indicating that the model has good discriminatory ability.Conclusion: Calculated-dose RAI is effective in the treatment of GD. The smaller thyroid volume and the higher 131I activity per gram of thyroid tissue are predictors of RAI efficacy in the treatment of GD.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] The success rate of radioactive iodine therapy for Graves' disease in iodine-replete area and affecting factors: a single-center study
    Park, Hyunju
    Kim, Hye In
    Park, Jun
    Park, So Young
    Kim, Tae Hyuk
    Chung, Jae Hoon
    Choi, Joon Young
    Kim, Sun Wook
    NUCLEAR MEDICINE COMMUNICATIONS, 2020, 41 (03) : 212 - 218
  • [42] EFFICACY OF RADIOACTIVE IODINE FOR THE TREATMENT OF HYPERTHYROIDISM
    Noreen
    Shoukat, Farkhanda
    Fatima, Nousheen
    INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 5 (09): : 9411 - 9415
  • [43] Predictive factors of a worse response to radioactive Iodine-I131 treatment in hyperthyroidism: outcome analysis in 424 patients. A single centre experience
    Finessi, Monica
    Bisceglia, Alessandro
    Passera, Roberto
    Giaccherino, Ruth Rossetto
    Pagano, Loredana
    Castellano, Giancarlo
    Ghigo, Ezio
    Bisi, Gianni
    Deandreis, Desiree
    ENDOCRINE, 2021, 73 (01) : 107 - 115
  • [44] Influence of Short-Term Dietary and Therapeutic Iodine Restriction on the Therapeutic Effects of Radioactive Iodine Therapy in Patients with Graves' Disease
    Nishio, Rie
    Uchida, Toyoyoshi
    Suzuki, Luka
    Onose, Hiroyuki
    Goto, Hiromasa
    Yamada, Emiko
    Satoh, Hiroaki
    Watada, Hirotaka
    THYROID, 2021, 31 (03) : 439 - 445
  • [45] Predictive Factors of Development of Graves' Ophthalmopathy for Patients with Juvenile Graves' Disease
    Jarusaitiene, Dalia
    Verkauskiene, Rasa
    Jasinskas, Vytautas
    Jankauskiene, Jurate
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2016, 2016
  • [46] Suppurative Lymphadenitis after Radioactive Iodine Therapy for Graves' Disease: A Rare Complication?
    Wong, Shi Hui Junice
    EUROPEAN THYROID JOURNAL, 2019, 8 (06) : 324 - 327
  • [47] Clinical factors influencing the success rate of radioiodine treatment for Graves' disease
    He, Meiwen
    Pan, Limeng
    Li, Yifan
    Wang, Yue
    Zhong, Xing
    Du, Yijun
    Pan, Tianrong
    DIABETES OBESITY & METABOLISM, 2024, 26 (10) : 4397 - 4409
  • [48] Cost-Effectiveness Analysis of Antithyroid Drug (Propylthiouracil) Compared to Radioactive Iodine for the Treatment of Graves' Disease in Ethiopia
    Mengistu, Habtamu Solomon
    Getahun, Kidus Tesfaye
    Alemayehu, Lake
    Gezahign, Sifrash
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2022, 14 : 221 - 229
  • [49] Radioactive Iodine Therapy of Graves' Disease in Patients Pretreated With Methimazole Without Radioiodine Uptake for Dose Estimation
    Mihailescu, Dan, V
    Hoscheit, Christine
    Fogelfeld, Leon
    ENDOCRINE PRACTICE, 2024, 30 (04) : 333 - 339
  • [50] Identification of patients with Graves' disease who benefit from high-dose radioactive iodine therapy
    Watanabe, Shiro
    Okamoto, Shozo
    Akikawa, Kazumasa
    Miyamoto, Noriyuki
    Okamura-Kawasaki, Miyuki
    Uchiyama, Yuko
    Takenaka, Junki
    Toyonaga, Takuya
    Hirata, Kenji
    Kudo, Kohsuke
    ANNALS OF NUCLEAR MEDICINE, 2022, 36 (11) : 923 - 930